BRAIN Biotech AG Total Liabilities
BRAIN Biotech AG total liabilities. Based on the latest financial reports, BRAIN Biotech AG (BNN) has total liabilities worth €64.50 Million EUR (≈ $75.40 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BRAIN Biotech AG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BRAIN Biotech AG (2012–2025)
Total liabilities of BRAIN Biotech AG from 2012 to 2025. This chart illustrates how BRAIN Biotech AG's total liabilities have evolved over time, based on quarterly financial data. Explore BRAIN Biotech AG long-term investment allocation to see how much of total assets are deployed in long-term investments.
BRAIN Biotech AG Competitors by Total Liabilities
The table below lists competitors of BRAIN Biotech AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vbt Yazilim AS
IS:VBTYZ
|
Turkey | TL1.15 Billion |
|
Gogoro Inc
NASDAQ:GGR
|
USA | $463.12 Million |
|
Futuretech II Acquisition Corp
NASDAQ:FTII
|
USA | $10.38 Million |
|
JR Invest SA
WAR:JRH
|
Poland | zł28.23 Million |
|
Stefstock
JSE:SSK
|
South Africa | ZAC5.08 Billion |
|
Lida Holdings Ltd
TW:4552
|
Taiwan | NT$1.64 Billion |
|
Dsr Wire
KO:069730
|
Korea | ₩85.17 Billion |
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
USA | $13.40 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down BRAIN Biotech AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BRAIN Biotech AG (BNN) total assets.
Liquidity & Leverage Metrics
BRAIN Biotech AG Total Liabilities Ratios Explained
BRAIN Biotech AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.35 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 35.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BRAIN Biotech AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BRAIN Biotech AG (2012–2025)
The table below shows the annual total liabilities of BRAIN Biotech AG from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | €64.50 Million ≈ $75.40 Million |
-13.83% |
| 2024-09-30 | €74.85 Million ≈ $87.51 Million |
+56.19% |
| 2023-09-30 | €47.92 Million ≈ $56.03 Million |
+9.55% |
| 2022-09-30 | €43.74 Million ≈ $51.14 Million |
+21.82% |
| 2021-09-30 | €35.91 Million ≈ $41.98 Million |
-21.95% |
| 2020-09-30 | €46.01 Million ≈ $53.79 Million |
-6.17% |
| 2019-09-30 | €49.03 Million ≈ $57.32 Million |
+11.88% |
| 2018-09-30 | €43.83 Million ≈ $51.24 Million |
+107.29% |
| 2017-09-30 | €21.14 Million ≈ $24.72 Million |
+2.70% |
| 2016-09-30 | €20.59 Million ≈ $24.07 Million |
-16.49% |
| 2015-09-30 | €24.65 Million ≈ $28.82 Million |
+119.64% |
| 2014-09-30 | €11.22 Million ≈ $13.12 Million |
+49.55% |
| 2013-09-30 | €7.51 Million ≈ $8.77 Million |
-1.08% |
| 2012-09-30 | €7.59 Million ≈ $8.87 Million |
-- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more